Inicio
Explorar
nav.journalClub
Tendencias
Más
synapse
⌘+K
Idioma
Español
Español
Allogeneic Transplant Outcomes in Patients Aged ≥70 Vs <70 with Fludarabine/Melphalan Conditioning and Post-Transplant Cyclophosphamide | Synapse
March 3, 2026
Allogeneic Transplant Outcomes in Patients Aged ≥70 Vs <70 with Fludarabine/Melphalan Conditioning and Post-Transplant Cyclophosphamide
HC
Howard Y. Chang
Amgen (United States)
SW
Staci Williamson
Oregon Health & Science University
DC
Daniel Chandra
Oregon Health & Science University
Ver todo
Puntos clave
Older patients show differential outcomes post-allogeneic transplant, particularly with specific conditioning regimens.
Key metrics indicate that age impacts overall survival rates and transplant success, emphasizing the need for tailored approaches.
Observational analysis focusing on patients receiving fludarabine and melphalan conditioning, followed by cyclophosphamide.
The findings suggest that further investigation is needed to refine treatment strategies for older transplant candidates.
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Cite This Study
Copy
Chang et al. (Sun,) studied this question.
synapsesocial.com/papers/69a76066c6e9836116a2d1e3
https://doi.org/https://doi.org/10.1016/j.jtct.2025.12.670